Abstract
Background: Multiple myeloma accounts for 1% of all types of malignancies and about 10 % of hematologic malignancies. Several clinical and laboratory variables help us to determine the prognosis of the disease. The present study is aimed at analyzing the various clinical presentations and studying hematological and biochemical parameters in determining prognosis in Myeloma.
Materials and Methods: 100 patients diagnosed as Multiple Myeloma who registered at hematology laboratory in a tertiary health care centre over a span of 3 years were studied. Clinical & radiological findings were recorded. Hematological & biochemical parameters were analyzed and compared between alive and expired patients. Based on the International Staging System (ISS) for multiple myeloma patients were staged as I, II & III and assessed correlation with prognosis. Statistical analysis was done by Student T test & ANOVA test.
Results: Most common clinical presentation was bone pain. Among the variables considered, serum creatinine and serum Beta 2 microglobulin showed statistically significant correlation with prognosis. The mean value of Serum creatinine and serum beta 2 microglobulin were 3.03 mg/dl and 5.8 mg/L respectively in expired patients. Staging by International Staging System was found to have good correlation with prognosis.
Conclusion: Serum beta 2 microglobulin and serum creatinine were found to be statistically significant and reliable prognostic indicators. Staging by International Staging System with prognostic correlation was also achieved by the present study.
Keywords: Multiple myeloma, serum Beta 2 microglobulin, prognosis.
References
- Sirohi B, Powles R. Multiple myeloma. Lancet 2004;363:875-87.
- Robert A Kyle,Gerts M A,et al: Review of 1027 patients with newly diagnosed Multiple myeloma.Mayo clinic proceedings, January 2003;Vol 78:21-33.
- P Kaur et al. Multiple myeloma: A clinical and pathological profile.G .J.O issue 16,2014:14-20
- National cancer registry programme . Consolidated report of the Population based cancer registries 1990-1996,Indian council of medical research,New Delhi. 2001
- Angela Oranger, Claudia Carbone et al:Cellular mechanisms of Multiple Myeloma Bone disease.Clinical and developmental immunology Volume 2013(2013),Article ID 289458,11 pages
- Bradwell A R, Carr Smith H D et al .Serum test for assessment of patients with Bence jones myeloma.Lancet 2003;361: 489-91
- Shaji Kumar,Teresa Kimlinger et al .Best Pract Clin Haematol.2010 Sep;23(3):433-451.
- Philip R Griepp et al : International staging system for Multiple Myeloma.J Clin Oncol23:3412-3420,2005
- Becker M R, Rompel R et al.Light chain Multiple myeloma with cutaneous AL amyloidosis. J Dtsch Dermatol Ges 2008 Sep;vol 6,issue9:744-745
- MAI YU-jie, QI Pei-jing et al. Clinical and laboratory features of newly diagnosed multiple myeloma:a retrospective single centre analysis. Chinese Medical journal,2007,120(19):1727-1729.
- Mital Hemendrakumar Chokshi,Shakera Nuruddinbhai Baji, Archit Shashankkumar Ganndi.Plasma cell leukemia : A comprehensive analysis of clinical & pathological features of 7 cases. Int J Med Sci Public Health.2014; 3(1):6-9
- Subramanian R,Basu D et al. Prognostic significance of bone marrow histology in Multiple myeloma. Indian J Cancer.2009 Jan- Mar;46(1):40-5
- Baraldi-Junkins C A,Beck A C,Rothstein G. Haematopoiesis and cytokines: relevance to cancer and aging, Hematol Oncol Clin North Am.2000;14:45-61.
- Bettini R, Redaelli S, Maino C, Bertuol S et al. Prognostic value of serum Beta 2 microglobulin in multiple myeloma. Recenti Proq Med. 2005 Feb; 96(2): 81-6
- Philip R. Griepp et al. International staging system for Multiple Myeloma. J Clin Oncol 23:3412-3420,2005.
Corresponding Author
Dr Roshny Jacob
Email: This email address is being protected from spambots. You need JavaScript enabled to view it.
DOI: https://dx.doi.org/10.18535/jmscr/v5i8.178
